Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-401-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
An in vitro skin irritation test ((EPISKIN Standard model (EPISKIN-SMTM)) was performed with bismuth oxy-iodide bromide according to OECD guideline and GLP principles. Based on this test it is concluded that bismuth oxy-iodide bromide is non-irritant in the in vitro skin irritation test under the experimental conditions described in this report.
An in vitro eye irritancy test was performed with bismuth oxy-iodide bromide (20% (w/w) solution) using the Bovine Corneal Opacity and Permeability test (BCOP test) according to OECD/ EC guidelines and GLP principles. It was concluded that bismuth oxy-iodide bromide is not irritant in this test.
Key value for chemical safety assessment
Skin irritation / corrosion
Link to relevant study records
- Endpoint:
- skin irritation: in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 - 23 June 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.46 (In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test)
- Version / remarks:
- Amended by EC No. 761/2009 OJ No. L220, 24 August 2009
- Deviations:
- no
- GLP compliance:
- yes
- Species:
- human
- Details on test animals or test system and environmental conditions:
- ENVIRONMENTAL CONDITIONS
- Temperature (°C): 36.1 - 37.5
- Humidity (%): 80-95 - Vehicle:
- unchanged (no vehicle)
- Amount / concentration applied:
- TEST MATERIAL
- Amounts applied: approximately 10 mg, 5 μl Milli-Q water to moisten skin. - Duration of treatment / exposure:
- 15 minutes
- Details on study design:
- TEST SITE
EPISKIN Standard ModelTM (EPISKIN-SMTM, 0.38 cm2, Lot no.: 10-EKIN-026). This model is a three-dimensional human epidermis model, which consists of adult human derived epidermal keratinocytes which have been seeded on a dermal substitute consisting of a collagen type I matrix coated with type IV collagen. The keratinocytes were cultured for 13 days, which results in a highly differentiated and stratified epidermis model comprising the main basal, supra basal, spinous and granular layers and a functional stratum corneum.
REMOVAL OF TEST SUBSTANCE
Washing: phosphate buffered saline - Time after start of exposure: 15 minutes
POST INCUBATION PERIOD
42 hours
SCORING SYSTEM
Cytotoxicity is expressed as the reduction of mitochondrial dehydrogenase activity measured by formazan production from MTT at the end of the treatment. Cell viability was calculated for each tissue as a percentage of the mean of the negative control tissues.
NEGATIVE CONTROL
Phosphate buffered saline (PBS, Invitrogen Corporation, Breda, The Netherlands).
POSITIVE CONTROL
5% (aq) sodium dodecyl sulphate (SDS, Sigma Aldrich, Zwijndrecht, The Netherlands) in PBS. - Irritation / corrosion parameter:
- % tissue viability
- Value:
- 100
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks:
- 8%
- Remarks on result:
- no indication of irritation
- Irritant / corrosive response data:
- The relative mean tissue viability obtained after 15 minutes treatment compared to the negative control tissues was 100%.
The positive control had a mean cell viability after 15 minutes exposure of 8%. The absolute mean OD570 of the negative control tissues was within the laboratory historical control data range. The standard deviation value of the percentage viability of three tissues treated identically was less than 18%, indicating that the test system functioned properly. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- An in vitro skin irritation test ((EPISKIN Standard model (EPISKIN-SMTM)) was performed according to OECD guideline and GLP principles. Based on this test it is concluded that bismuth oxy-iodide bromide is non-irritant in the in vitro skin irritation test under the experimental conditions described in this report.
- Executive summary:
An in vitro skin irritation test ((EPISKIN Standard model (EPISKIN-SMTM)) was performed according to OECD guideline and GLP principles. The relative mean tissue viability obtained after 15 minutes treatment compared to the negative control tissues was 100%. The positive control had a mean cell viability after 15 minutes exposure of 8%. Since the mean relative tissue viability was above 50% after 15 minutes treatment bismuth oxy-iodide bromide
is considered to be non-irritant.
Reference
Bismuth oxy-iodide bromide was checked for possible direct MTT reduction by adding the test substance to MTT medium. Because no colour change was observed it was concluded that bismuth oxy-iodide bromide did not
interact with MTT.Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not irritating)
Eye irritation
Link to relevant study records
- Endpoint:
- eye irritation: in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12 - 15 July 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD guideline 437 “Bovine corneal opacity and permeability (BCOP) test method for identifying ocular corrosives and severe irritants”
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: In Vitro Techniques in Toxicology Database (INVITTOX) protocol 124. Bovine Opacity and Permeability Assay - SOP of Microbiological Associates Ltd., 1999.
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Gautheron P., Dukic M., Alix D. and Sina J.F., Bovine corneal opacity and permeability test: An in vitro assay of ocular irritancy. Fundam Appl Toxicol 18:442-449, 1992.
- Deviations:
- no
- Principles of method if other than guideline:
- pH: 7.5 (50g/ L)
- GLP compliance:
- yes
- Specific details on test material used for the study:
- pH: 7.5 (50g/ L)
- Vehicle:
- physiological saline
- Amount / concentration applied:
- TEST MATERIAL
- Amount applied (volume or weight with unit): approx. 750 ul of 20% (w/w) test substance solution per cornea
NEGATIVE CONTROL
- Amount applied: 750 µl of physiological saline per cornea
POSITIVE CONTROL
Amount applied: 750 µl per cornea
Concentration (if solution): 20% (w/v) Imidazole
- Duration of treatment / exposure:
- 240 minutes
- Details on study design:
- TEST SITE
- Isolated bovine cornea
REMOVAL OF TEST SUBSTANCE
- Washing (if done): yes
- Time after start of exposure: 240 minutes
CONTROLS
Negative control: A negative control, physiological saline (Merck, Darmstadt, Germany) was included to detect non-specific changes in the test system and to provide a baseline for the assay endpoints.
Positive control: 20% (w/w) Imidazole (Merck Schuchardt DHG, Germany) [CAS Number 288-32-4] solution prepared in physiological saline.
SCORING SYSTEM:
- After exposure the cornea is thoroughly rinsed to remove the test substance followed by immediate opacity measurement and permeability evaluation of the cornea. The permeability is evaluated by sodium fluorescein.
- The mean opacity and mean permeability values (OD490) were used for each treatment group to calculate an in vitro score:
In vitro irritancy score (IVIS) = mean opacity value + (15 x mean OD490 value).
TOOL USED TO ASSESS SCORE:
- opacitymeter and microplate reader - Irritation parameter:
- in vitro irritation score
- Remarks:
- 240 minutes
- Run / experiment:
- mean of 3 replica
- Value:
- ca. 0.7
- Negative controls validity:
- valid
- Remarks:
- 0
- Positive controls validity:
- valid
- Remarks:
- 79
- Other effects / acceptance of results:
- The corneas treated showed opacity values ranging from 0 to 1 and permeability values ranging from 0.020 to 0.057. The corneas were clear after the 240 minutes of treatment. No pH effect of the test substance was observed on the rinsing medium. Hence, the in vitro irritancy scores ranged from 0.3 to 1.9 after 240 minutes of treatment. The individual in vitro irritancy scores for the negative controls ranged from -0.9 to 0.0. The individual positive control in vitro irritancy scores ranged from 111 to 139. The corneas treated with the positive control were turbid after the 240 minutes of treatment.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- An in vitro eye irritancy test was performed with bismuth oxy-iodide bromide (20% (w/w) solution) using the Bovine Corneal Opacity and Permeability test (BCOP test) according to OECD/ EC guidelines and GLP principles. It was concluded that bismuth oxy-iodide bromide is not irritant in this test.
- Executive summary:
An in vitro eye irritancy test was performed with bismuth oxy-iodide bromide (20% (w/w) solution) using the Bovine Corneal Opacity and Permeability test (BCOP test) according to OECD/EC guidelines and GLP principles.
Reliable positive and negative controls were included. The corneas were clear after the 240 minutes of treatment. The in vitro irritancy scores ranged from 0.3 to 1.9 after 240 minutes of treatment. Based on these data, it is concluded that this test is valid and that bismuth oxy-iodide bromide (tested as a 20% (w/w) solution) is not severe irritant in the Bovine Corneal Opacity and Permeability test under the experimental conditions described in this report.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not irritating)
Respiratory irritation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An in vitro skin irritation test ((EPISKIN Standard model (EPISKIN-SMTM)) was performed with bismuth oxy-iodide bromide according to OECD/ EC guidelines and GLP principles. The relative mean tissue viability obtained after 15 minutes treatment compared to the negative control tissues was 100%. The positive control had a mean cell viability after 15 minutes exposure of 8%. Since the mean relative tissue viability was above 50% after 15 minutes treatment bismuth oxy-iodide bromide is considered to be non-irritant.
An in vitro eye irritancy test was performed with bismuth oxy-iodide bromide (20% (w/w) solution) using the Bovine Corneal Opacity and Permeability test (BCOP test) according to OECD/EC guidelines and GLP principles. Reliable positive and negative controls were included. The corneas were clear after the 240 minutes of treatment. The in vitro irritancy scores ranged from 0.3 to 1.9 after 240 minutes of treatment. Based on these data, it is concluded that this test is valid and that bismuth oxy-iodide bromide (tested as a 20% (w/w) solution) is not severe irritant in the Bovine Corneal Opacity and Permeability test under the experimental conditions described in this report.
Justification for classification or non-classification
Based on the available data, bismuth oxy-iodide bromide is not classified as irritant according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.